Target family: Chemokine receptors (type: gpcr)
Target: CCR1

Ligand: BMS-817399 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9 pIC50
Reference (Journal): Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis.
Published in: J Med Chem

Ligand: BP-CCL3 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.8 pKi
Reference (Journal): Synthesis and characterization of fluorescent and photoactivatable MIP-1alpha ligands and interactions with chemokine receptors CCR1 and CCR5.
Published in: J Med Chem

Ligand: BX 471 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1.
Published in: J Biol Chem

Ligand: CCL13 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: CCL14 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.4 pKi
Reference (Journal): Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP-1beta.
Published in: Br J Pharmacol

Ligand: CCL15 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.9 pIC50
Reference (Journal): Characterisation of macrophage inflammatory protein-5/human CC cytokine-2, a member of the macrophage-inflammatory-protein family of chemokines.
Published in: Eur J Biochem

Ligand: CCL18 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): CCL18 exhibits a regulatory role through inhibition of receptor and glycosaminoglycan binding.
Published in: PLoS ONE

Ligand: CCL23 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.9 pKi
Reference (Journal): Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP-1beta.
Published in: Br J Pharmacol

Ligand: CCL3 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP-1beta.
Published in: Br J Pharmacol

Ligand: CCL3 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Monocyte chemoattractant protein-3 is a functional ligand for CC chemokine receptors 1 and 2B.
Published in: J Biol Chem

Ligand: CCL3 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Synthesis and characterization of fluorescent and photoactivatable MIP-1alpha ligands and interactions with chemokine receptors CCR1 and CCR5.
Published in: J Med Chem

Ligand: CCL3 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor.
Published in: J Biol Chem

Ligand: CCL4 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Monocyte chemoattractant protein-3 is a functional ligand for CC chemokine receptors 1 and 2B.
Published in: J Biol Chem

Ligand: CCL4 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP-1beta.
Published in: Br J Pharmacol

Ligand: CCL5 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Monocyte chemoattractant protein-3 is a functional ligand for CC chemokine receptors 1 and 2B.
Published in: J Biol Chem

Ligand: CCL5 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor.
Published in: J Biol Chem

Ligand: CCL7 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.1 pKi
Reference (Journal): Study of the HIV-1 receptors CD4, CXCR4, CCR5 and CCR3 in the human and rat testis.
Published in: Mol Hum Reprod

Ligand: CCL7 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.1 pKi
Reference (Journal): Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP-1beta.
Published in: Br J Pharmacol

Ligand: CCL8 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: CCX354 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Patent): 3-(imidazolyl)-pyrazolo[3,4-b]pyridines

Ligand: compound 2b-1 [PMID: 12614873] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.7 pIC50
Reference (Journal): Structure-activity relationships of xanthene carboxamides, novel CCR1 receptor antagonists.
Published in: Bioorg Med Chem

Ligand: CP-481,715 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8 pKd
Reference (Journal): CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases.
Published in: J Biol Chem

Ligand: Flu-CCL3 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.1 pKi
Reference (Journal): Synthesis and characterization of fluorescent and photoactivatable MIP-1alpha ligands and interactions with chemokine receptors CCR1 and CCR5.
Published in: J Med Chem

Ligand: MLN-3897 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.100000381469727 pIC50

Ligand: [125I]CCL2 (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.4 pKd
Reference (Journal): Characterization of functional chemokine receptors (CCR1 and CCR2) on EoL-3 cells: a model system to examine the role of chemokines in cell function.
Published in: J Pharmacol Exp Ther

Ligand: [125I]CCL3 (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd
Reference (Journal): Monocyte chemotactic protein-3 (MCP3) interacts with multiple leukocyte receptors. C-C CKR1, a receptor for macrophage inflammatory protein-1 alpha/Rantes, is also a functional receptor for MCP3.
Published in: J Biol Chem

Ligand: [125I]CCL3 (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd
Reference (Journal): Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors.
Published in: J Biol Chem

Ligand: [125I]CCL3 (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd
Reference (Journal): Characterization of functional chemokine receptors (CCR1 and CCR2) on EoL-3 cells: a model system to examine the role of chemokines in cell function.
Published in: J Pharmacol Exp Ther

Ligand: [125I]CCL5 (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.2 pKd
Reference (Journal): Characterization of functional chemokine receptors (CCR1 and CCR2) on EoL-3 cells: a model system to examine the role of chemokines in cell function.
Published in: J Pharmacol Exp Ther

Ligand: [125I]CCL7 (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.2 pKd
Reference (Journal): Monocyte chemotactic protein-3 (MCP3) interacts with multiple leukocyte receptors. C-C CKR1, a receptor for macrophage inflammatory protein-1 alpha/Rantes, is also a functional receptor for MCP3.
Published in: J Biol Chem

Ligand: [125I]CCL8 (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.3 pKd
Reference (Journal): Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors.
Published in: J Biol Chem

Ligand: UCB35625 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.020000457763672 pIC50
Reference (Journal): A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry.
Published in: J Biol Chem

Ligand: vMIP-II (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.1 pIC50
Reference (Journal): A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus.
Published in: Science